Inhibikase Therapeutics (IKT) Other Gross PP&E Adjustments (2020 - 2025)
Inhibikase Therapeutics (IKT) has 6 years of Other Gross PP&E Adjustments data on record, last reported at -$5.4 million in Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 43.28% to -$5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.4 million, a 43.28% decrease, with the full-year FY2025 number at -$5.4 million, down 43.28% from a year prior.
- Other Gross PP&E Adjustments reached -$5.4 million in Q4 2025 per IKT's latest filing, down from $117224.0 in the prior quarter.
- Over the last five years, Other Gross PP&E Adjustments for IKT hit a ceiling of $117224.0 in Q3 2025 and a floor of -$5.4 million in Q4 2025.
- A 5-year average of -$1.0 million and a median of -$89635.0 in 2024 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: tumbled 205.82% in 2024, then skyrocketed 500.36% in 2025.
- Tracing IKT's Other Gross PP&E Adjustments over 5 years: stood at -$2.3 million in 2021, then fell by 11.14% to -$2.5 million in 2022, then dropped by 8.78% to -$2.7 million in 2023, then crashed by 37.47% to -$3.8 million in 2024, then tumbled by 43.28% to -$5.4 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for IKT at -$5.4 million in Q4 2025, $117224.0 in Q3 2025, and $82306.0 in Q2 2025.